Clinical Trial: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07181473) titled 'A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors' on Sept. 01.

Brief Summary: The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors.

The main objectives of this study are :

* To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ101

* to show preliminary antitumor activity in patients with advanced solid tumors

Participants will:

* Receive intravenous (IV) infusions of TJ101 at escalating dose ...